Alcon

• Go to www.alconlabs.com

Alcon is a PLATINUM level sponsor of the American Optometric Association.

Investing in the Future of Sight

Preserving, enhancing and restoring sight has been Alcon's sole mission for over 60 years.

As the world's leader in ophthalmology, Alcon works each day to deliver best-in-class products to patients everywhere through cultivating strong partnerships with doctors in more than180 countries.

Every year, Alcon makes the largest corporate investment in eye care research and development, according to the company.

In fact, over the next five years, Alcon plans to invest more than $3 billion in efforts to prevent and, one day, eliminate blindness.

Two of the newest products resulting from this commitment to research and development are the AcrySof^® ReSTOR^® Aspheric intraocular lens (IOL) and ICaps^® AREDS Softgels.

The AcrySof ReSTOR Aspheric is the latest addition to the AcrySof ReSTOR family of lenses, the most frequently implanted presbyopia-correcting IOL for cataract patients.

The AcrySof ReSTOR Aspheric IOL is the first and only presbyopia-correcting IOL to offer apodized diffractive step heights and aspheric optic design.

This unique IOL is designed to optimally deliver light and energy to the retina by distributing the appropriate amount of light to near and distance focal points, regardless of the lighting situation.

The AcrySof ReSTOR Aspheric IOL provides patients with a full range of vision, from near to far, without dependence on glasses.

ICaps AREDS Softgels, an easy-to-swallow, two-a-day version of Alcon's traditional AREDS tablet formulation, are set to be released in February 2008.

The AREDS combination of vitamins and minerals, which is preferred most by retinal specialists, was studied in the National Eye Institute Age-Related Eye Disease Study (AREDS) and found to be beneficial for patients at high risk of progression of age-related macular changes.

The ICaps Softgels are an addition to a family of eye vitamins including both a multivitamin formula as well as a lutein and zeaxanthin formula.

"We are excited about introducing these two new advancements to doctors and their patients," said Dave Sattler, director of Professional Relations. "We look forward to launching additional eye care products in the coming years that are the result of our substantial investment in eye care research and development."